Sphingolipid Metabolic Pathway Impacts Thiazide Diuretics Blood Pressure Response: Insights From Genomics, Metabolomics, and Lipidomics

BACKGROUND: Although hydrochlorothiazide (HCTZ) is a well‐established first‐line antihypertensive in the United States, <50% of HCTZ treated patients achieve blood pressure (BP) control. Thus, identifying biomarkers that could predict the BP response to HCTZ is critically important. In this study...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Am Heart Assoc
Autori principali: Shahin, Mohamed H., Gong, Yan, Frye, Reginald F., Rotroff, Daniel M., Beitelshees, Amber L., Baillie, Rebecca A., Chapman, Arlene B., Gums, John G., Turner, Stephen T., Boerwinkle, Eric, Motsinger‐Reif, Alison, Fiehn, Oliver, Cooper‐DeHoff, Rhonda M., Han, Xianlin, Kaddurah‐Daouk, Rima, Johnson, Julie A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2017
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5778957/
https://ncbi.nlm.nih.gov/pubmed/29288159
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.117.006656
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi